Pancreatic cyst found by chance: follow-up scans

The main guidance

ACG 2018 (American College of Gastroenterology): diagnosis and surveillance of pancreatic cysts for the general gastroenterologist. (ACG 2018)
European 2018 guideline (European Study Group on Cystic Tumours of the Pancreas): evidence-based statements on each cyst type. (European 2018)
ACR 2017 white paper (American College of Radiology): an algorithm for cysts found by chance on CT or MRI that ends either with a cyst benign or slow enough to stop follow-up, or with a next step. (ACR 2017)
AGA 2015 (American Gastroenterological Association) guideline on cysts without symptoms, summarized here from an open-access review. (Shah 2025 review)
Kyoto 2024 (International Association of Pancreatology): evidence-based guidelines for IPMN, the most common type found by chance, revising the 2017 international consensus guidelines. (Kyoto 2024)(ACG 2018)

Who it applies to

ACG says its guideline does not apply to people with a strong family history of pancreatic cancer or a gene change known to raise the risk. (ACG 2018) For them, see pancreatic cancer screening. ACG also says most pancreatic cysts cause no symptoms, so symptoms should be put down to a cyst only with care. (ACG 2018)

Cyst types and which need no follow-up

Common pancreatic cyst types and follow-up (simplified)
Type	What guidance says
Pseudocyst	Linked to pancreatitis. ACG: no further tests if diagnosed on the first scan and history and there are no symptoms.
Serous cystadenoma	Very low risk. ACG: no further tests. European: follow up for 1 year if the diagnosis is clear, then only if symptoms appear; if the diagnosis is unsure, follow up as for a branch-duct IPMN.
Side-branch IPMN	The most common cyst found by chance, with a low risk of turning into cancer. Surveillance is offered.
Mucinous cystic neoplasm (MCN)	Almost only in women. European: under 4 cm with no nodule or symptoms, MRI, EUS or both every 6 months in the first year, then yearly if unchanged.
Main-duct IPMN, solid-pseudopapillary neoplasm	Higher risk. Beyond screening: EUS or a specialist team.

Sources for the table: ACG recommendations and cyst types tables, and the European statements 5.3, 6.2 and 6.3. (ACG 2018)(European 2018) ACG says imaging alone names the cyst type correctly only 40% to 50% of the time, and a cyst that stays unclear may get a second type of scan or an EUS. (ACG 2018)

MRI or EUS

ACG: MRI or MRCP is the test of choice, as it uses no radiation and shows whether the cyst joins the main pancreatic duct. A pancreas-protocol CT or EUS (endoscopic ultrasound) is an alternative for people who cannot have MRI. MRCP is also the preferred test for follow-up. (ACG 2018)
European: follow-up may need lifelong imaging, and repeated CT adds radiation; MCN follow-up uses MRI, EUS or both. (European 2018)
AGA 2015: limits EUS to cysts with at least two high-risk features. (Shah 2025 review)
Kyoto 2024: adds EUS findings to the list of risk features when EUS is done. (Kyoto 2024)

How often

European: for an IPMN with no risk features, a check at 6 months in the first year, then yearly. For people with a risk feature, older people and those with severe other illness, every 6 months. (European 2018)
ACG: for a presumed IPMN or MCN with no concerning features, cyst size sets how often scans are done, in a chart in the guideline. (ACG 2018)
ACR 2017: sets schedules by age and size. Under 65: yearly for 5 years, then every 2 years for 4 more years. Age 65 to 79 with a cyst under 1.5 cm: every 2 years for 10 years. Age 80 or over at first finding, if follow-up suits the person's health: stop when the cyst is stable for 4 years. (Shah 2025 review)

How long, and when it stops

When guidance stops follow-up of a cyst with no risk features
Guidance	When follow-up stops
AGA 2015	After 5 years with no change, or when the person is no longer a candidate for surgery
ACR 2017	After 9 to 10 years with no change and no risk features, or on reaching age 80
Kyoto 2024	Small branch-duct IPMN unchanged for 5 years: stopping or continuing are both reasonable; stop with a life expectancy under 10 years
ACG 2018	When no longer a candidate for surgery; review over 75 and decide one by one at 76 to 85
European 2018	Lifelong while the person is fit for surgery

Sources for the table: the Shah 2025 review for AGA, ACR and the Kyoto 10-year rule; the Kyoto abstract; the ACG recommendations 15 and 16; the European guideline. (Shah 2025 review)(Kyoto 2024)(ACG 2018)(European 2018)

Features that change the plan

ACG lists these high-risk features for mucinous cysts (IPMN and MCN); any of them leads to EUS or a specialist team: (ACG 2018)

Yellowing of the skin (jaundice) or acute pancreatitis caused by the cyst
A raised CA 19-9 blood level with no benign cause
A nodule or solid part in the cyst or pancreas
A main pancreatic duct wider than 5 mm, or a change in its width with shrinking of the pancreas beyond it
A cyst over 3 cm, or growth of more than 3 mm a year

ACG adds that new or worsening diabetes, or fast growth, leads to a short-interval MRI or EUS. (ACG 2018) The European guideline links a higher risk with a duct of 5 to 9.9 mm, growth of 5 mm or more a year, CA 19-9 over 37 U/mL, symptoms, a nodule under 5 mm, or a cyst of 40 mm or more. (European 2018)

Routine age-based screening

A cyst found by chance does not replace the routine screenings for your age. For other findings on a scan, see kidney cyst found by chance, adrenal mass found by chance, ovarian cyst found by chance and lung nodule found by chance.

Where they differ:

When to stop. AGA stops after 5 stable years and ACR after 9 to 10 years or at age 80. (Shah 2025 review) Kyoto allows either stopping or continuing after 5 years for small unchanged cysts. (Kyoto 2024) ACG reviews follow-up after 75, and the European guideline lists lifelong follow-up while a person is fit for surgery. (ACG 2018)(European 2018)
Size. ACG counts a cyst over 3 cm as a high-risk feature; the European guideline uses 40 mm. (ACG 2018)(European 2018)
Growth. ACG uses more than 3 mm a year; the European guideline uses 5 mm or more a year. (ACG 2018)(European 2018)
EUS. AGA 2015 limits EUS to cysts with at least two high-risk features; ACG lists EUS for any one of them. (Shah 2025 review)(ACG 2018)
Serous cystadenoma. ACG lists no further tests; the European guideline lists 1 year of follow-up. (ACG 2018)(European 2018)
Evidence. ACG says the evidence behind cyst guidelines is poor and calls for prospective studies. (ACG 2018)

Your doctor decides what your result means for you.

Questions people ask

Are pancreatic cysts found by chance common?

Yes. ACG cites 2.4% to 13.5% of people without symptoms, rising with age, and about 40% on MRI scans in people over 70. Cysts over 2 cm were found in only 0.8%. (ACG 2018)

Does every pancreatic cyst need follow-up?

No. ACG says a pseudocyst or a very low-risk cyst such as a serous cystadenoma needs no further tests, and people not fit for surgery should not have further tests for a cyst found by chance. (ACG 2018)

Which test is used to follow a cyst?

ACG prefers MRI with MRCP, with no radiation, and EUS for people who cannot or choose not to have MRI. The European guideline uses MRI, EUS or both. (ACG 2018) (European 2018)

How often are the scans?

The European guideline lists a check at 6 months in the first year, then yearly, for a presumed IPMN with no risk features. ACR sets the schedule by age and size, for example every 2 years for 10 years for a cyst under 1.5 cm at age 65 to 79. (European 2018) (Shah 2025 review)

When does follow-up stop?

It depends on the body: AGA after 5 stable years, ACR after 9 to 10 stable years or at age 80, ACG reviews it after 75, and the European guideline lists lifelong follow-up while a person is fit for surgery. (Shah 2025 review) (ACG 2018) (European 2018)